The Protocol Review and Monitoring System (PRMS) evaluates the scientific merit, quality, and progress of all cancer related clinical trials at the AECC. The functions of the PRMS are: a) to review and evaluate all protocols for scientific merit, feasibility, and quality;(b) to monitor accrual in order to assure that protocols meet their accrual goals in a timely fashion;(c) to ensure that there are no competing studies with completely overlapping eligibility, and that there is adequate justification and patient resources in circumstances where it may be desirable to have more than one protocol for a specific indication;and (d) to provide recommendations as to whether AECC investigator-initiated studies are of sufficient scientific merit to warrant allocation of Protocol Specific Research Support (PSRS) and/or other resources required for conduct of the study. The PRMS functions are carried out by the Protocol Review and Monitoring Committee (PRMC), a multidisciplinary group including pathologists, radiologists, biostatisticians, nurses, pharmacists, physician scientists from surgical, medical, pediatric, gynecological, and radiation oncology. PRMC members have experience in various therapeutic modalities (i.e., cytotoxic and targeted therapies, immunotherapy, radiation) and expertise in various stages of drug development (Phases I, II, 111 trials) and translational science. The PRMC performs a complete scientific, feasibility, and administrative review of all institutional investigator-initiated and industry-sponsored cancer related protocols. All NCI-sponsored protocols that have undergone prior peer review undergo an expedited administrative review for feasibility and overlapping eligibility with other trials.
The Protocol Review and Monitoring System (PRMS) evaluates the scientific merit, quality, prioritization, and progress of all the cancer related clinical trials at the Albert Einstein Cancer Center (AECC). As an NCI designated Cancer Center, AECC contributes to the national effort to reduce morbidity and mortality from cancer.
|Gradissimo, Ana; Lam, Jessica; Attonito, John D et al. (2018) Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Biomarkers Prev 27:1407-1415|
|Mirabello, Lisa; Clarke, Megan A; Nelson, Chase W et al. (2018) The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses 10:|
|Drelon, Coralie; Belalcazar, Helen M; Secombe, Julie (2018) The Histone Demethylase KDM5 Is Essential for Larval Growth in Drosophila. Genetics 209:773-787|
|Hudgins, Adam D; Tazearslan, Cagdas; Tare, Archana et al. (2018) Age- and Tissue-Specific Expression of Senescence Biomarkers in Mice. Front Genet 9:59|
|Willis, Ian M; Moir, Robyn D; Hernandez, Nouria (2018) Metabolic programming a lean phenotype by deregulation of RNA polymerase III. Proc Natl Acad Sci U S A 115:12182-12187|
|Hayama, Ryo; Sparks, Samuel; Hecht, Lee M et al. (2018) Thermodynamic characterization of the multivalent interactions underlying rapid and selective translocation through the nuclear pore complex. J Biol Chem 293:4555-4563|
|Martynova, Elena; Bouchard, Maxime; Musil, Linda S et al. (2018) Identification of Novel Gata3 Distal Enhancers Active in Mouse Embryonic Lens. Dev Dyn 247:1186-1198|
|Huang, Kezhen; Mukherjee, Subhajit; DesMarais, Vera et al. (2018) Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitis. Pediatr Res 83:1031-1040|
|Bines, Jose; Tevaarwerk, Amye J (2018) Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy. Cancer :|
|Mathew, Deepti; Wang, Yanhua; Van Arsdale, Anne et al. (2018) Expression of ?V-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia. Int J Gynecol Cancer 28:363-370|
Showing the most recent 10 out of 1508 publications